StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note published on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock. Cellectis Price Performance Shares of NASDAQ CLLS traded up $0.36 during mid-day trading on Friday, reaching $3.35. 272,116 shares of the company traded hands, compared […]
StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research report report published on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock. Cellectis Stock Up 0.6 % Shares of CLLS opened at $2.51 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio […]
StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Cellectis Price Performance NASDAQ:CLLS opened at $2.51 on Friday. The company’s 50-day moving average price is $2.62 and its 200-day moving average price is $2.65. […]
Shares of Cellectis S.A. (NASDAQ:CLLS – Get Free Report) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.71 and traded as high as $2.82. Cellectis shares last traded at $2.75, with a volume of 20,196 shares trading hands. Cellectis Stock Up 0.4 […]
Baillie Gifford & Co. decreased its holdings in shares of Cellectis S.A. (NASDAQ:CLLS – Free Report) by 13.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,418,996 shares of the biotechnology company’s stock after selling 220,900 shares during the quarter. Baillie Gifford […]